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albimanus and Anopheles stephensi mosquitoes 
to ivermectin
Staci M. Dreyer, Kelsey J. Morin and Jefferson A. Vaughan* 
Abstract 
Background: Vector control is a crucial element of anti-malaria campaigns and works best when there is a thorough 
knowledge of the biology and behaviour of the Anopheles vector species responsible for transmitting malaria within 
a given locale. With the push to eradicate malaria stronger than ever, there is a growing need to develop and deploy 
control strategies that exploit the behavioural attributes of local vector species. This is especially true in regions where 
the vectors are exophagic (i.e., prefer to bite outdoors), exophilic (i.e., prefer to remain outdoors), and zoophagic (i.e., 
as likely to feed on non-humans as humans). One promising strategy targeting vectors with these behavioural traits 
is the administration of avermectin-based endectocides, such as ivermectin, to humans and livestock. When ingested 
in a blood meal, ivermectin has been shown to reduce mosquito survivorship and fecundity in a number of Anoph-
eles species. In this study, the relative toxicity of ivermectin was compared between two zoophagic, exophilic malaria 
vectors—Anopheles albimanus and Anopheles stephensi.
Results: Toxicity of ivermectin was assessed using membrane feedings, intrathoracic injections, and mosquito feed-
ings on treated mice. When ingested in a blood meal, ivermectin was much less toxic to An. albimanus (4-day oral 
 LC50 = 1468 ng/ml) than to An. stephensi (4-day oral  LC50 = 7 ng/ml). However when injected into the haemocoel of 
An. albimanus, ivermectin was much more toxic (3-day parenteral  LC50 = 188 ng/ml). Because the molecular targets 
of ivermectin (i.e., glutamate-gated chloride channels) reside outside the midgut in nerves and muscles, this sug-
gests that ingested ivermectin was not readily absorbed across the midgut of An. albimanus. In contrast, ivermectin 
was considerably more toxic to An. stephensi when ingested (4-day oral  LC50 = 7 ng/ml) than when injected (3-day 
parenteral  LC50 = 49 ng/ml). This suggests that metabolic by-products from the digestion of ivermectin may play a 
role in the oral toxicity of ivermectin to An. stephensi. Blood meal digestion and subsequent oviposition rates were 
significantly hindered in both species by ingested ivermectin but only at concentrations at or above their respective 
oral  LC50 concentrations. To test mosquitocidal activity of ivermectin in a live host system, two groups of three mice 
each received subcutaneous injections of either ivermectin (600 µg/kg BW) or saline (control). One day after injection, 
the ivermectin-treated mice (n = 3) exhibited significant mosquitocidal activity against both An. stephensi (85% mor-
tality vs 0% in control-fed) and, to a lesser degree, An. albimanus (44% mortality vs 11% in control-fed). At 3 days, the 
mosquitocidal activity of ivermectin-treated mice waned and was effective only against An. stephensi (31% mortality 
vs 3% in control-fed).
Conclusions: Ivermectin was not uniformly toxic to both Anopheles species. Previous studies indicate that ivermec-
tin is a good choice of endectocide to use against malaria vectors in southeast Asia and Africa. However, these data 
suggest that ivermectin may not be the optimal endectocide to use in Central America or the Caribbean where An. 
albimanus is a major malaria vector species. If endectocides are to be used to help eradicate malaria, then additional 
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Background
Malaria remains a major public health problem through-
out the tropics [1] and is transmitted by Anopheles mos-
quitoes. Vector control is an essential element of malaria 
control programmes. Throughout sub-Saharan Africa, 
indoor residual spraying (IRS) and insecticide treated 
bed-nets (ITN) have been successful vector control tac-
tics because the primary vector species, Anopheles gam-
biae feed almost exclusively on people sleeping in their 
houses at night and rest inside the house after blood-
feeding [2–4]. Other important malaria vector species in 
Africa (e.g., Anopheles arabiensis), Asia (e.g., Anopheles 
stephensi) and the neotropics (e.g., Anopheles albimanus) 
are exophagic (i.e., prefer to bite outdoors), exophilic 
(i.e., prefer to rest outdoors), and/or zoophagic (i.e., 
as likely to feed on non-humans as humans) [5]. Effec-
tive control of Anopheles species with these behavioural 
characteristics requires alternative tactics. The primary 
non-human blood sources for zoophagic malaria vectors 
are peridomestic livestock (cattle, goats). Livestock rep-
resent mosquito blood sources that humans can manage 
and control. It is logical that any comprehensive strategy 
against zoophagic malaria vectors should include some 
sort of livestock management component. One tactic to 
control zoophagic malaria vectors is to treat livestock 
with ivermectin.
Ivermectin is a lipophilic drug that belongs to the 
avermectin class of macrocyclic lactone compounds. 
Ivermectin acts as an endectocide (i.e., kills both endo-
parasites and ectoparasites). Ivermectin binds to and acti-
vates the glutamate-gated chloride channels of nerve and 
muscle cells of a wide variety of nematode and arthropod 
species, causing uncontrolled influx of chloride ions into 
the cells and leading to paralysis and death of the organ-
ism [6]. Ivermectin has a high safety profile in humans 
and livestock [7] and is one of the most commonly-used 
anti-helminthic drug in the livestock industry to control 
intestinal nematodes.
The large-scale administration of oral ivermectin to 
people has become a cornerstone in the global eradi-
cation campaign against human onchocerciasis and 
lymphatic filariasis [8, 9]. The recommended dose of 
ivermectin used to treat humans for filarial infection 
[i.e., 150  mg/kg body weight (BW)] yields peak plasma 
concentrations of ca. 40–45 ng/ml [10]. At these plasma 
concentrations, ivermectin can significantly reduce the 
survival of Anopheles mosquitoes that ingest treated 
blood. Anopheles species shown to be susceptible to iver-
mectin at these concentrations include major vectors 
from Africa (An. gambiae [11–13], An. arabiensis [14]), 
Southeast Asia (Anopheles campestris, Anopheles dirus, 
Anopheles minimus, Anopheles swandwongporni [15]) 
and Latin America (Anopheles aquasalis [16], Anopheles 
darlingi [17]). Pilot field trials in western Africa indicate 
that the mass drug administration of ivermectin against 
onchocerciasis and lymphatic filariasis can simultane-
ously reduce survival of An. gambiae and local malaria 
transmission [18, 19].
Similarly, ivermectin treatment of livestock could the-
oretically reduce vector abundance and lower malaria 
transmission [20, 21]. At the same time, treatment of 
herds may also reduce tick and intestinal worm bur-
dens, leading to increases in livestock weight gain, milk 
production, and ultimately increases in the health and 
economic prosperity of livestock owners. However, it 
is currently unknown if all species of Anopheles vectors 
are equally susceptible to ivermectin. This study com-
pared the relative toxicity of ivermectin to two known 
malaria vectors: Anopheles (Nyssorhynchus) albimanus, 
a major vector along the coastal regions of Mexico, Cen-
tral America, the Caribbean, and northern South Amer-
ica [22], and Anopheles (Cellia) stephensi, an important 
malaria vector in southern and western Asia [23]. Both 
species are highly zoophagic, exophilic and exophagic, 
making them appropriate species to target with a strategy 
involving ivermectin treatment of livestock.
Methods
Mosquitoes
Laboratory colonies of An. albimanus STECL strain and 
An. stephensi STE2 strain were obtained as eggs through 
BEI Resources (Manassas, VA USA). Mosquitoes were 
reared in the University of North Dakota insectary at a 
photoperiod of 12-h light:12-h dark and a temperature of 
26 °C. Eggs were hatched in trays of dechlorinated water. 
Larvae were fed fish food (Tetra Pond Sticks, Tetra, 
Blacksburg, VA USA) ground to a fine powder in an elec-
tric coffee grinder. Pupae were placed into ca. 28  l wire 
mesh cages to emerge. Adults were given access to water 
and a sugar source. Female mosquitoes 3–7 days old for 
use in toxicity studies were aspirated from rearing cages 
into smaller (ca. 0.5  l), cylindrical cardboard contain-
ers with mesh tops at a density of 15–40 mosquitoes per 
cage.
efficacy data will be needed to define the activity of specific endectocides against the major malaria vector species of 
the world.
Keywords: Anopheles albimanus, Anopheles stephensi, Endectocide, Ivermectin, Vector control
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Membrane feeding
For each membrane feeding trial, age-matched cohorts of 
An. albimanus and An. stephensi were blood fed simul-
taneously on identical ivermectin preparations. For each 
feeding trial, stock solutions were prepared fresh by dilut-
ing powdered technical grade ivermectin (Sigma-Aldrich, 
St. Louis MO, USA) into dimethyl sulfoxide (DMSO) 
at a concentration of 2  mg/ml. The stock solution was 
diluted to starting concentrations in phosphate-buffered 
saline (PBS). From that, serial dilutions were made in 
1.5 ml polypropylene microfuge tubes containing whole 
bovine blood with sodium heparin (10  U/ml, Pel-Freez 
Biologicals, Rodgers AR, USA) for a total volume of 1 ml. 
A control group (i.e., 10  µl PBS added to 990  µl blood) 
was included with each trial. Prior to feeding, the tubes 
were inverted a minimum of three times to mix the 
solutions and kept in warm water. Natural sausage cas-
ing (Dewied International, San Antonio TX, USA) was 
rinsed thoroughly to remove salt preservative and cut to 
fit across the bottom of glass membrane feeders. Feeders 
were connected to one another with rubber tubing and 
heated water (ca. 37 °C) was circulated to warm the feed-
ers. Membrane feeders were placed one per cage, and 
the blood-ivermectin mixtures were pipetted into the 
feeders. Mosquitoes were allowed to feed for ca. 30 min. 
Unfed mosquitoes were removed. Engorged mosqui-
toes were maintained in the insectary and provided 
with cotton soaked in a 10% sucrose solution. Cages 
were checked every day. Dead mosquitoes were counted 
and removed. For most trials, the number of surviving 
mosquitoes was counted at 4 days. In one trial, survival 
counts were extended to 5 days to determine if mortality 
had stabilized. By day 5, the rate of mortality stabilized 
and became asymptotic. Thus, 4 days was selected as an 
appropriate time on which to base  LC50 determinations 
for oral toxicity. After preliminary trials to determine an 
appropriate range of concentrations, feedings were rep-
licated five times using 4–5 ivermectin concentrations, 
plus a control, for each feeding trial.
Intrathoracic injection
Mosquitoes were immobilized by chilling (− 20  °C for 
ca. 20 s), then quickly transferred to filter paper onto a 
chill table (BioQuip, Rancho Dominguez, CA, USA). To 
perform injections, a semi-automated micro-injector 
(TriTech Research, Los Angeles CA, USA) was fitted 
with fine-tipped glass needles made with a micropipette 
puller (World Precision, Sarasota FL, USA). A stock 
solution was prepared as described above and from 
that, serial dilutions were made in 1.5  ml polypropyl-
ene microfuge tubes containing an insect salt solution 
[24]. Mosquitoes were injected with 0.4  µl of solution 
into the thorax, near the base of the wing. Mosquitoes 
were then placed into appropriately labeled recovery 
containers. Injected mosquitoes were provided 10% 
sucrose solution and checked daily for 3  days. Dead 
mosquitoes were counted and removed over the course 
of 3 days, at which time the surviving mosquitoes were 
counted. In one trial, survival counts were extended to 
4 days to determine if mortality had stabilized. By day 
4, the rate of mortality stabilized and became asymp-
totic. Thus, 3 days was selected as an appropriate time 
on which to base  LC50 determinations for parenteral 
toxicity. After preliminary trials to determine an appro-
priate range of concentrations, injections were repli-
cated three times for An. stephensi and four times for 
An. albimanus, using 4–5 ivermectin concentrations 
plus a control at each injection trial.
Fecundity
Mosquitoes were fed with membrane feeders on blood 
containing various doses of ivermectin, as described pre-
viously. Anopheles stephensi were given a single experi-
mental blood meal and monitored for egg production. 
However during colony rearing of An. albimanus, it was 
noted that this species required more than one blood 
feeding in order to produce sufficient eggs to maintain 
the colony. To accurately assess the effect of ivermectin 
on An. albimanus fecundity, it was necessary that con-
trol-fed females undergo full gonotrophic development. 
Therefore, An. albimanus were first given a normal blood 
meal (i.e., cow blood with no drugs). Unfed mosquitoes 
were removed and engorged An. albimanus were held for 
2  days without oviposition sites. The mosquitoes were 
then offered a second, experimental blood meal. Unfed 
mosquitoes were removed. One day after experimental 
blood meals, fully engorged mosquitoes were immobi-
lized by chilling and each mosquito was placed into an 
individual 30  ml glass vial with screened top and single 
strip of filter paper on which to rest. Raisins were placed 
on top of each vial as a sucrose source. After mosquitoes 
fully recovered and could fly, 2 ml of aged tap water was 
introduced into the vial for mosquitoes to lay their eggs. 
Vials were maintained at 26  °C for 5  days, after which 
vials were filled with ethanol to kill the parent mosquito 
and the eggs and hatchlings. Eggs and hatchling larvae 
were counted the same day. Midguts and ovaries from 
the parent mosquitoes were dissected to quantify blood 
digestion and ovarian development, based on the Sella 
scale [25]. For simplicity, Sella stages were combined into 
two groups: early stages (Sella stages II, III, IV) indicating 
that minimal vitellogenesis had occurred, and late stages 
(Sella stages V, VI, VII) indicating that complete or nearly 
complete vitellogenesis had occurred.
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Feeding on treated mice
Ivermectin stock solution (2000  µg/ml DMSO) was 
diluted in saline to a working concentration of 80 µg/ml. 
Three outbred, white mice were weighed and subcutane-
ously injected with an appropriate volume of ivermectin 
solution to achieve a dose of 600 µg/kg BW. Three con-
trol mice were injected subcutaneously with equivalent 
volumes of saline. The next day (= 24 h after treatment), 
each mouse was anesthetized (pentobarbital 60  µg/gm 
BW, ip) and individually placed onto a screened-top 
container containing 20–30 An. albimanus mosquitoes. 
Mosquitoes were allowed to feed for ca. 20  min, after 
which anesthetized mice were immediately transferred 
to screen-top containers containing 20–30 An. stephensi 
mosquitoes. Mosquitoes were allowed ca. 30 min to feed. 
Afterwards, mice were returned to the vivarium. Unfed 
mosquitoes were removed from the cages. Engorged 
mosquitoes were provided with moistened cotton and a 
sucrose source (chopped prune), and maintained at 26 °C. 
Four days after blood feeding, surviving mosquitoes 
from each mouse were subdivided into aliquots of 3–6 
mosquitoes each and gently introduced into new con-
tainers containing a cup of water for oviposition. Three 
days after mice had received injections, a fresh batch of 
An. albimanus and An. stephensi mosquitoes were fed on 
the mice and the process described above was repeated. 
Dead mosquitoes were removed and counted daily for 
6  days, after which the number of mosquitoes left alive 
and total number of eggs laid were counted.
Data analysis
Mosquito mortalities observed within experimen-
tal groups were adjusted for any mortality that 
occurred within corresponding control groups using 
Abbott’s formula [26]. Only experimental trials having 
control mortalities less than 20% were used for further 
data analyses. Log-probit analyses were conducted on 
the corrected percent moralities to estimate  LC50 values 
(Minitab Inc., State College PA, USA). Mosquito survi-
vorship was analysed with a Kaplan–Meier survival anal-
ysis and Log-rank Mantel-Cox test (GraphPad Software, 
La Jolla, CA, USA). Mosquito fecundities (i.e., average 
number of eggs laid per female) were compared among 
treatments using one-way analysis of variance (ANOVA) 
on  log10 transformed egg counts. If an ANOVA showed a 
significant effect due to treatment, the Tukey Honest Sig-
nificant Differences (Tukey HSD) post hoc test was used 
to separate statistical differences between groups. Rates 
of mosquito oviposition and egg hatch, and blood diges-
tion (based on early Sella scores) in treatment groups 
were compared with their corresponding controls with 
Chi square analyses (Statistix, Tallahassee FL, USA). A 
0.05 level of significance was used throughout.
Results
Membrane feeding and intrathoracic inoculations
A total of 573 An. stephensi and 582 An. albimanus were 
used to determine the relative oral toxicities of ingested 
ivermectin. A total of 606 An. stephensi and 293 An. albi-
manus were used to determine the relative parenteral 
toxicities of inoculated ivermectin. When ingested, iver-
mectin was much more toxic to An. stephensi (oral 4-day 
 LC50 = 7 ng/ml) than to co-fed An. albimanus (oral 4-day 
 LC50 = 1468  ng/ml; Table  1). Similarly, intrathoracially-
inoculated ivermectin was more toxic to An. stephensi 
(parenteral 3-day  LC50 = 49 ng/ml) than to An. albimanus 
(parenteral 3-day  LC50 = 188  ng/ml; Table  1). Lethal-
ity of ingested ivermectin did not occur immediately. 
Instead, mosquito mortality progressed over a period of 
several days after ingestion of treated blood and treated 
Table 1 Comparative toxicities of ivermectin to Anopheles mosquitoes when ingested (oral  LC50) or injected (parenteral 
 LC50)
LC50 values are expressed as ng/ml. Italic text indicates data resulting from the present study
Species Oral  LC50 (95% CL) Parenteral 3-day  LC50 (95% CL) Citation
An. arabiensis 7.9 (6.2, 9.9) at 9 days post-feed – [14]
An. stephensi 7.0 (5.2, 8.6) at 4 days post-feed 48.8 (42.6, 56.9) present study
An. minimus 16.3 (11.6, 19.4) at 7 days post-feed – [15]
An. gambiae s.l. 19.8 (± 2.8) at 9 days post-feed – [11]
An. gambiae s.s. 22.4 (18.0, 26.9) at 5 days post-feed – [12]
An. campestris 26.4 (21.9, 30.5) at 7 days post-feed – [15]
An. sawadwongporni 26.9 (24.8, 28.8) at 7 days post-feed – [15]
An. dirus 55.6 (52.3, 59.1) at 7 days post-feed – [15]
An. aquasalis 47.0 (44.7, 49.4) at 5 days post-feed – [16]
An. albimanus 1468.0 (1153.5, 1965.5) at 4 days post-feed 187.9 (136.2, 239.0) present study
An. darlingi 43.2 (37.5, 48.6) at 7 days post-feed – [17]
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mosquitoes of both species experienced significant 
reduction in survivorship over a 4-day period (Fig.  1). 
Significant reductions of mosquito survival occurred 
with An. stephensi at all doses tested (Fig.  1a) whereas 
with An. albimanus, significant reductions occurred only 
at the highest doses tested (Fig. 1b). Mosquito mortality 
occurred more rapidly when ivermectin was inoculated 
versus when the drug was ingested (Fig. 2).  
Fecundity
The oviposition rate for control-fed An. stephensi after 
ingesting one blood meal (82%, n = 38) was similar to 
that of control-fed An. albimanus after ingesting two 
blood meals (84%, n = 62) (Table  2). Significant reduc-
tions in oviposition rates occurred in An. stephensi 
(33%, n = 6, cχ2 = 4.1, p = 0.04) and An. albimanus (61%, 
n = 51, cχ2 = 6.5, p = 0.01) that ingested ivermectin at 32 
and 1300 ng/ml respectively (Chi square tests, cχ2 ≥ 4.1, 
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Fig. 1 Daily proportion of surviving mosquitoes after ingesting ivermectin at various concentrations. a Anopheles stephensi, b Anopheles albimanus. 
Survival curves for ivermectin-exposed mosquitoes were compared statistically to the survival curves of control mosquitoes using Log-rank 
Mantel-Cox tests. Test values and p values at each ivermectin concentration are shown
Page 6 of 10Dreyer et al. Malar J  (2018) 17:148 
p < 0.05) but not for mosquitoes that ingested lower 
concentrations of ivermectin (Table  2, Chi square tests, 
p > 0.68).
There were no differences in the average number of 
eggs laid per ovipositing female between control-fed and 
ivermectin-fed mosquitoes at any of the dosages tested 
for both An. stephensi (F = 2.05 df = 4, 58; p = 0.10) and 
An. albimanus (F = 1.48, df = 2, 126; p = 0.23) (Table  2). 
However, the egg hatching rates for An. stephensi that 
ingested 8  ng/ml ivermectin (56%, n = 12, cχ2 = 43.1, 
p < 0.0001) and An. albimanus that ingested 1300 ng/ml 
ivermectin (18%, n = 51, cχ2 = 389.1, p < 0.0001) were sig-
nificantly less than egg hatch rates of the corresponding 
control-fed groups (73 and 48%, respectively) (Table  2). 
The egg hatch rate for An. stephensi that ingested 32 ng/
ml ivermectin (52%) was lower than that of control-fed 
mosquitoes (73%), but the difference was not quite sta-
tistically significant (cχ2 = 3.62, p = 0.057). This was likely 
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Fig. 2 Daily proportion of surviving mosquitoes after intrathoracic inoculation of ivermectin at various concentrations. a Anopheles stephensi, b 
Anopheles albimanus. Survival curves for ivermectin-exposed mosquitoes were compared statistically to the survival curves of control mosquitoes 
using Log-rank Mantel-Cox tests. Test values and p values at each ivermectin concentration are shown
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due to the excessive adult mortality that occurred at this 
dose and the small number of surviving females (n = 6) 
left to oviposit (Table  2). By multiplying oviposition 
rates, fecundity and hatch rates for each treatment group 
(Table 2, last column), notable reductions in F1 larva pro-
duction occurred only at doses that exceeded the oral 
 LC50 values for each species (see Table 1). Five days after 
blood feeding, the majority (≥ 90%) of control-fed mos-
quitoes in both species had either laid their eggs, or were 
fully gravid in late Sella stages. However with increasing 
dosages of ivermectin, the proportion of mosquitoes that 
laid eggs by day 5 diminished (Fig. 3). With exception of 
An. albimanus fed at 100  ng/ml concentration, signifi-
cantly greater proportions of ivermectin-fed mosquitoes 
retained undigested blood in their guts and underdevel-
oped ovaries (early Sella stages), compared to midguts 
and ovaries observed in control-fed mosquitoes (Fisher’s 
exact test, p values ≤ 0.007, Fig. 3).
Feeding on treated mice
One day after mice received injections, there were sig-
nificant reductions in the 6-day survival rate of An. 
stephensi (15%) and An. albimanus (56%) fed on iver-
mectin-injected mice compared to mosquitoes fed 
on saline-injected control mice (100 and 89%, respec-
tively, Chi square tests with Yate’s correction, cχ2 > 11, 
p < 0.001; Table  3). Average fecundity in An. stephensi 
fed on ivermectin-treated mice (0.9 ± 1.6 eggs/female) 
was significantly less than mosquitoes fed on control 
mice (46.1 ± 25.9 eggs/female) (t test, T = 8.2, df = 13, 
p < 0.0001). No significant reduction in fecundity was 
observed for An. albimanus fed on ivermectin-treated 
mice. Three days after mice were treated with iver-
mectin, there remained a significant, albeit smaller, 
reduction in the 6-day survival of An. stephensi fed on 
Table 2 Reproductive capacity of Anopheles mosquitoes ingesting various concentrations of  ivermectin via  membrane 
feeder
Anopheles stephensi mosquitoes were blood fed one time on either treated or untreated blood. Anopheles albimanus mosquitoes were blood fed twice; once on 
untreated blood and again, 2 days later, on either treated or untreated blood. Engorged mosquitoes were held individually in oviposition vials. Superscripts indicate 
statistically significant differences for parameters within a species
Mosquito species Conc (ng/ml) Total no. 
surviving 
females
Oviposition rate 
of survivors (%)
Geometric mean no. of eggs 
laid per ovipositing female 
(95% CI)
Overall 
hatch rate 
(%)
Theoretical number of larvae 
produced per 1000 surviving 
females
An. stephensi 0 38 82A 50.1 (34.9, 71.9)A 73.3A 30,113
4 14 71A 41.6  (22.0, 78.5)A 70.1A 20,705
8 12 83A 29.8 (13.1, 46.7)A 56.1B 13,876
16 12 83A 24.7 (15.8, 56.2)A 76.0A 15,581
32 6 33B 10.4 (2.5, 43.0)A 52.4A 1798
An. albimanus 0 62 84A 50.0 (41.0, 60.0)A 47.9A 20,118
300 53 87A 49.2 (41.2, 60.6)A 46.2A 19,776
1300 51 61B 39.2  (30.9, 50.0)A 18.4B 4400
0%
20%
40%
60%
80%
100%
0 4 8 16 32
Concentration (ng/ml)
Anopheles stephensi Early Sella
 Late Sella
 Oviposited
46 31 25 29 25
0%
20%
40%
60%
80%
100%
0 100 300 900
Concentration (ng/ml)
Anopheles albimanus 
62 64 38 31
Fig. 3 Proportions of Anopheles stephensi and Anopheles 
albimanus that completed vitellogensis and successfully oviposited 
(= Oviposited), underwent extensive vitellogenesis but did not 
oviposit (= late Sella), or underwent minimal vitellogenesis and 
minimal blood meal digestion (= early Sella). Mosquitoes were 
dissected 5 days after ingesting various concentrations of ivermectin 
via membrane feeding. Numbers above histograms indicate numbers 
of mosquitoes examined
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ivermectin-treated mice (62%) versus that of An. ste-
phensi fed on control mice (96%) (Chi square tests with 
Yate’s correction, value = 16, p < 0.001; Table  3). No sig-
nificant difference was observed in the 6-day survival of 
An. albimanus fed on mice 3  days after treatment. By 
3  days after mouse injections, there were no significant 
differences in mosquito fecundity for either species fed 
on ivermectin-treated versus control mice (Table 3).
Discussion
Ivermectin ingested in a blood meal has been shown 
to be extremely potent against at least eight different 
anopheline species that have been tested to-date [11–
17]. This study found ingested ivermectin to be similarly 
potent against An. stephensi (Table 1). However, An. albi-
manus is the most ivermectin-tolerant Anopheles species 
evaluated to-date, with an oral  LC50 over 25-fold greater 
than other species tested. The relative insensitivity of An. 
albimanus to ingested ivermectin was evident regardless 
of whether ivermectin was administered in cow blood via 
membrane feeders or via mosquito feedings on treated 
mice (Table 3).
To investigate the mechanism(s) of this insensitivity, 
serial dilutions of ivermectin were injected directly into 
the haemocoels of An. albimanus and An. stephensi and 
the resulting parenteral  LC50 values were compared 
with the oral  LC50 values derived from membrane 
feeding trials (Table  1). The rationale for injecting 
ivermectin is that the target molecules for ivermectin 
(i.e., glutamate-gated chloride channels) reside within 
nervous and muscle tissue outside of the midgut [27]. 
Injection bypasses the midgut. When injected directly 
into the haemocoel of An. albimanus, ivermectin not 
only worked more rapidly (Fig.  2B) but was also ten-
fold more toxic than when it was ingested in a blood 
meal (Table 1). This indicates that ingested ivermectin 
was poorly absorbed across the gut of An. albimanus. 
Even so, injected ivermectin was still significantly less 
toxic to An. albimanus  (LC50 = 188 ng/ml) than to An. 
stephensi  (LC50 = 49  ng/ml), suggesting that the bind-
ing affinity of ivermectin and/or its stimulatory effect 
on the glutamate-gated chloride channels of An. albi-
manus was less than that of the glutamate-gated chlo-
ride channels of An. stephensi. The relative insensitivity 
of An. albimanus to ingested ivermectin may be attrib-
utable to (1) poor absorption of ivermectin across the 
gut of An. albimanus, (2) potential structural differ-
ences between the glutamate-gated chloride channels 
among anopheline species, or (3) more efficient detoxi-
fication processes occurring in An. albimanus com-
pared to other species of Anopheles tested.
Curiously, ivermectin was significantly more toxic 
to An. stephensi when ingested  (LC50 = 7  ng/ml) than 
when injected  (LC50 = 49  ng/ml). This suggests that 
ivermectin metabolites resulting from mosquito diges-
tion of the blood meal may have a contributory role in 
the overall oral toxicity of ivermectin to An. stephensi.
Ingestion of ivermectin also reduced the reproductive 
potential of An. albimanus and An. stephensi by inhib-
iting blood meal digestion, vitellogenesis, oviposition 
rate, fecundity, and egg hatch (Fig.  3, Tables  2 and 3). 
However, statistically significant reductions in these 
reproductive parameters occurred only when mos-
quitoes ingested ivermectin at or above the respective 
 LC50 concentrations for each species. This is similar to 
that reported for ivermectin in An. arabiensis [14] but 
stands in contrast to results reported for An. aquasa-
lis [16], where significant reductions in egg produc-
tion and hatching were observed after mosquitoes had 
ingested ivermectin at a substantially lower potency, 
i.e., a concentration equivalent to the  LC5 for that spe-
cies (= 18 ng/ml). Defining the effects of ingested iver-
mectin on mosquito reproduction is important because 
significant net reductions in mosquito reproduction 
could still act to reduce mosquito populations, even at 
sub-lethal concentrations (see Table 2).
Table 3 Survival and fecundity of Anopheles mosquitoes at 6 days after feeding on ivermectin treated versus untreated 
mice
Mice received subcutaneous injections of either ivermectin (600 mg/kg BW) or saline (control group). Three mice were used for each treatment. Cohorts of age-
matched mosquitoes (n = sample size) were blood-fed 1 day after injections and 3 days after injections
Species Treatment 1 day after mouse injections 3 days after mouse injections
Percent surviving (n) Eggs per female (± SD) Percent surviving (n) Eggs per female 
(± SD)
An. stephensi Ivermectin 15% (52) cχ2 = 76.5
p < 0.001
0.9 ± 1.6 T = 8.2
df = 13
p < 0.001
62% (66) cχ2 = 15.7
p < 0.001
30.8 ± 8.7 T = 1.0
df = 4
p = 0.373Control 100% (56) 46.1 ± 25.9 96% (48) 44.7 ± 18.8
An. albimanus Ivermectin 56% (56) cχ2 = 11.3
p < 0.001
4.7 ± 8.1 T = 1.5
df = 17
p = 0.143
95% (57) cχ2 = 0.9
p = 0.332
25.2 ± 7.2 T = 0.2
df = 4
p = 0.864Control 89% (52) 12.8 ± 13.2 85% (48) 24.8 ± 10.0
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According to the recommendations of most commer-
cial manufacturers of endectocide livestock products, 
a subcutaneous dose of ivermectin at 200  mg/kg BW is 
standard for control of intestinal nematodes. At that dose 
and mode of delivery, the peak plasma concentrations 
of ivermectin in cattle ranges between 30 and 46 ng/ml 
[28–30]. Field studies have shown that this amount of 
ivermectin (200 mg/kg BW) in the blood of treated cattle 
is sufficient to cause significant mortality and reproduc-
tive losses in several species of Anopheles mosquitoes, 
including An. arabiensis [31], Anopheles culicifacies and 
An. stephensi [32]. This study suggests that plasma levels 
of ivermectin in this range would not produce any mor-
tality or loss of reproduction in An. albimanus that feed 
on ivermectin-treated cattle.
To successfully implement endectocides for vector con-
trol, it is essential to fill the gaps in knowledge about how 
different mosquito species react to ivermectin. This study 
found wide differences in oral and parenteral toxicities 
of ivermectin to the Asian vector, An. stephensi, and the 
Latin American vector An. albimanus. These studies uti-
lized long established laboratory strains of mosquitoes. 
An important next step will be to define comparative tox-
icities of ivermectin and other endectocides against field 
strains of Anopheles mosquitoes.
Conclusions
Ivermectin has been shown to be a promising candidate 
for Anopheles vector control in many parts of the world. 
However, there are several important species of Anoph-
eles that have yet to be tested for their susceptibility to 
ivermectin. This study found that An. stephensi was 
highly susceptible to ivermectin. Conversely, An. albi-
manus was nearly impervious to the effects of ivermec-
tin when compared to other Anopheles species tested to 
date. Significant mortality and sterility of An. albimanus 
were achieved only at ivermectin concentrations so high 
that they would not be feasible or desirable to use in live-
stock. Fortunately, there are a number of other related 
avermectin-based endectocides currently registered for 
use in livestock in many countries. Further efficacy test-
ing of alternative endectocides should be conducted 
against Central and South American malaria vectors if 
endectocides are to be successfully implemented in the 
Americas for zoophagic vector control.
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